MPs lobby Merck for U.K. Vioxx deal

Now Parliament wants Merck to give U.K. patients a cut. MPs are hopping mad that the company is settling with U.S. Vioxx claimants to the tune of $4.85 billion but refuses to make a deal in Britain. They're inviting the drugmaker to the table this week as the deadline for court action against Merck approaches.

Some 500 British patients have been unable to sue in part because they can't afford to risk paying Merck's legal bills if they lose. Contingency fee lawyers consider filing suit against the drug giant too risky, The Times reports. So 44 MPs have signed a motion calling the situation "unjust," and the government has been asked to investigate.

- see the article in The Times
- check out the other Pharmalot item

Related Articles:
Vioxx plaintiffs sign on, deal proceeds. Report
Merck settling Vioxx claims for $4.85B. Report
Vioxx deal faces pitfalls. Report
Court appoints Vioxx special master. Report
Vioxx settlement spawns mega-chatter. Report

Suggested Articles

Alnylam is ready to follow on its Onpattro launch with an FDA nod for Givlaari. But the drug's safety profile is giving analysts reason to pause.

FDA nominee Stephen Hahn faced questions from Senators on Wednesday on topics including drug pricing, biosimilars, opioids and more.

BMS’ Opdivo-Yervoy combo been game-changing in late-stage melanoma. But when it comes to expanding the pair’s reach, the company has hit a roadblock.